LAZ Form 4: Alexandra Soto Receives 2,380 RSUs; Vesting Through 2028
Rhea-AI Filing Summary
Insider stock award reinvestment increased beneficial ownership. Lazard Chief Operating Officer Alexandra Soto received 2,380 restricted stock units (RSUs) on 08/15/2025 under dividend-equivalent reinvestment provisions. Each RSU converts to one share of common stock. The filing shows 2,380 RSUs added to the reporting position and reports beneficial ownership of 259,312 shares following the transaction; this total excludes 113,872 shares the filer holds directly or indirectly. The RSUs vest in three tranches: 583 around March 2, 2026; 864 around March 1, 2027; and 933 around March 1, 2028.
Positive
- Acquisition of 2,380 RSUs through dividend-equivalent reinvestment, increasing the reporting person's equity stake.
- Clear vesting schedule disclosed: 583 RSUs vest ~03/02/2026, 864 RSUs vest ~03/01/2027, 933 RSUs vest ~03/01/2028.
- Beneficial ownership disclosed as 259,312 shares following the transaction, with 113,872 shares separately noted as directly or indirectly owned.
Negative
- None.
Insights
TL;DR: Insider received dividend-reinvested RSUs, modestly increasing reported beneficial ownership without immediate sale or purchase.
The Form 4 documents an acquisition of 2,380 RSUs by COO Alexandra Soto on 08/15/2025 through dividend-equivalent reinvestment of existing RSU awards. The RSUs convert one-for-one into common shares and vest in defined tranches through 2028. This is a non-cash, compensatory equity accrual rather than an open-market purchase and therefore reflects compensation mechanics rather than a secondary market vote of confidence.
TL;DR: Routine compensation-related equity grant reported; vesting schedule and ownership disclosure are compliant and clear.
The filing discloses the nature and vesting schedule of additional RSUs granted via dividend reinvestment, and separately reports total beneficial ownership levels excluding specified shares. The report is executed under power of attorney and signed on 08/19/2025, meeting filing formalities. No dispositions, sales, or new option grants are shown that would raise governance or liquidity concerns.